Sanofi's Adlyxin Merely Another Option For Type 2 Diabetes Treatments
Executive Summary
After a long wait, lixisenatide has little to distinguish itself from the five GLP-1 products already on the market.
You may also be interested in...
FDA’s Advisory Committees Just Can’t Say “No”
Who says an advisory committee stop is a risky proposition? FDA’s advisors have voted in favor of approval on each of the last 12 products they’ve reviewed.
Keeping Track: FDA Approves Adlyxin, Accepts Brineura, Lowers Hurdle For Xadago
The latest drug development news and highlights from our FDA Performance Tracker.
Can A Safety Study Support A Superiority Claim? Barely, US FDA Advisors Say
Using a clinical trial originally designed for safety to support an efficacy superiority claim poses unique challenges that can make reliance upon a single study for regulatory purposes potentially risky.